Access cutting-edge nausea and vomiting treatment through this clinical trial at a research site in The Bronx. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this The Bronx location
Preparing your pre-screening questions…
Access nausea and vomiting specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related nausea and vomiting treatment provided free
Check if you qualify for this nausea and vomiting clinical trial in The Bronx, NY
No-Cost Study Care
Local to The Bronx
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.
Sponsor: Montefiore Medical Center
Yes, this clinical trial (NCT06382012) has an active research site in The Bronx, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for nausea and vomiting treatment options in The Bronx, NY, this clinical trial (NCT06382012) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our The Bronx research site is actively enrolling participants for this clinical trial. You'll receive care from experienced nausea and vomiting specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all nausea and vomiting clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in The Bronx — not just this study.
Browse Heart Attack Trials in The Bronx →